It was found that commercialization of the high blood pressure combination drugs including Boryung's Fimasartan is imminent. If this product is approved, a total of four products will form treatment options in the hypertension treatment lineup leading to Kanarb-Kanarb Plus-Dukarb. Through this, it is expected that the diversity of patient prescriptions can be secured.

According to the industry on the 4th, Boryung recently submitted an application for permission for the tentatively named Dukarb Plus to the MFDS.

Dukarb Plus is a complex in which a diuretic component, HCTZ, is bonded to Dukarb (Fimasartan-Amlodipine), a second complex. Already, Boryung has conducted phase 3 clinica